This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative motor neuron disease characterized by muscle weakness, wasting, spasticity, and weight loss, and eventually by respiratory failure. There is a degeneration and loss of motor neurons in the spinal cord, brainatem, and cerebral cortex. Death typically occurs within 3 to 4 years of the onset of the disease, although some patients may live considerably longer. [1,2] In the past few years there has been a substantial amount of research into the pathophysiology and treatment of ALS. Although a wide variety of therapeutic approaches have been attempted, until recently there was no drug that had an effect on the natural course of the disease. Riluzole, a glutamate antagonist, is the first such agent and the first drug approved for ALS treatment. Two placebo-controlled trials have demonstrated that the drug prolongs survival in patients with ALS. [3,4] Other investigational therapeutic approaches to the treatment of ALS include the use of neurotrophic factors, antioxidants, and other glutamate inhibitors. This article reviews the agents now available and those under investigation for the treatment of ALS, and discusses potential future approaches to therapy.
Pathogenesis of ALS.
A number of hypotheses concerning the pathogenesis of ALS have been proposed. These include: oxidative stress mediated by free radicals; neural toxicity (excitotoxicity) caused by the excessive stimulation of glutamate receptors by excitatory amino acids (e.g., glutamate, aspartate); a deficiency of neuronal growth factors; and autoimmunity (calcium channel autoantibodies). [5] There is growing evidence that oxidative stress is important in the initiation of the disease. [6] This hypothesis is supported by the discovery of mutations in the gene encoding for Cu/Zn superoxide dismutase (SOD1) in patients with familial ALS. [7] Glutamate is the principal excitatory neurotransmitter in the brain, and there is evidence that glutamate excitotoxicity is an important factor in the propagation of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
